IFN-γ directly inhibits TNF-α-induced osteoclastogenesis in vitro and in vivo and induces apoptosis mediated by Fas/Fas ligand interactions

Immunology Letters

Volumn 137, Issue 1-2, 2011, Pages 53-61

  Kohara, Haruka ^a   Kitaura, Hideki ^b   Fujimura, Yuji ^a   Yoshimatsu, Masako ^a   Morita, Yukiko ^a   Eguchi, Toshiko ^a   Masuyama, Ritsuko ^a   Yoshida, Noriaki ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

Author keywords

Apoptosis; Fas; IFN ; Osteoclast; TNF

Indexed keywords

CD4 ANTIBODY; CD8 ANTIBODY; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; MESSENGER RNA; PROTEIN ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE DESTRUCTION; BONE MARROW CELL; CELL COUNT; CELL NUCLEUS; CELL STIMULATION; CELL STRAIN; CELL STRAIN NFATC1; CONTROLLED STUDY; FASL GENE; GENE; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; STEM CELL;

ANIMALS; APOPTOSIS; BONE RESORPTION; CELLS, CULTURED; FAS LIGAND PROTEIN; INTERFERON-GAMMA; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, NUDE; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; OSTEOGENESIS IMPERFECTA; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79954423688     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2011.02.017     Document Type: Article

References (41)

1. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
2. Teitelbaum S.L. Bone resorption by osteoclasts. Science 2000, 289:1504-1508.
3. Takayanagi H., Sato K., Takaoka A., Taniguchi T. Interplay between interferon and other cytokine systems in bone metabolism. Immunol Rev 2005, 208:181-193.
4. Kobayashi K., Takahashi N., Jimi E., Udagawa N., Takami M., Kotake S., et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000, 191:275-286.
5. Kim N., Kadono Y., Takami M., Lee J., Lee S.H., Okada F., et al. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med 2005, 202:589-595.
6. Kitaura H., Sands M.S., Aya K., Zhou P., Hirayama T., Uthgenannt B., et al. Marrow stromal cells and osteoclast precursors differentially contribute to TNF-alpha-induced osteoclastogenesis in vivo. J Immunol 2004, 173:4838-4846.
7. Kitaura H., Zhou P., Kim H., Novack D.V., Ross F.P., Teitelbaum S.L. M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest 2005, 115:3818-3827.
8. Tracey K.J., Cerami A. Tumor necrosis factor, other cytokines and disease. Ann Rev Cell Biol 1993, 9:317-343.
9. Wong M., Ziring D., Korin Y., Desai S., Kim S., Lin J., et al. TNF-alpha blockade in human diseases: mechanisms and future directions. Clin Immunol 2008, 126:121-136.
10. Nurmohamed M.T., Dijkmans B.A. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs 2005, 65:661-694.
11. Le Goff B., Blanchard F., Berthelot J., Heymann D., Maugars Y. Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis. Joint Bone Spine 2010, 77:201-205.
12. Kotake S., Udagawa N., Takahashi N., Matsuzaki K., Itoh K., Ishiyama S., et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999, 103:1345-1352.
13. Fox S.W., Fuller K., Bayley K.E., Lean J.M., Chambers T.J. TGF-beta 1 and IFN-gamma direct macrophage activation by TNF-alpha to osteoclastic or cytocidal phenotype. J Immunol 2000, 165:4957-4963.
14. Kitaura H., Nagata N., Fujimura Y., Hotokezaka H., Tatamiya M., Nakao N., et al. Interleukin-4 directly inhibits tumor necrosis factor-alpha-mediated osteoclast formation in mouse bone marrow macrophages. Immunol Lett 2003, 88:193-198.
15. Mohamed S.G., Sugiyama E., Shinoda K., Taki H., Hounoki H., Abdel-Aziz H.O., et al. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells. Bone 2007, 41:592-602.
16. Horwood N.J., Elliott J., Martin T.J., Gillespie M.T. IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. J Immunol 2001, 166:4915-4921.
17. Nagata N., Kitaura H., Yoshida N., Nakayama K. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-γ possibly induced from non-T cell population. Bone 2003, 33:721-732.
18. Kitaura H., Nagata N., Fujimura Y., Hotokezaka H., Yoshida N., Nakayama K. Effect of IL-12 on TNF-alpha-mediated osteoclast formation in bone marrow cells: apoptosis mediated by Fas/Fas ligand interaction. J Immunol 2002, 169:4732-4738.
19. Yamada A., Takami M., Kawawa T., Yasuhara R., Zhao B., Mochizuki A., et al. Interleukin-4 inhibition of osteoclast differentiation is stronger than that of interleukin-13 and they are equivalent for induction of osteoprotegerin production from osteoblasts. J Immunol 2007, 120:573-579.
20. Udagawa N., Horwood N.J., Elliott J., Mackay A., Owens J., Okamura H., et al. Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation. J Exp Med 1997, 185:1005-1012.
21. Kitaura H., Tatamiya M., Nagata N., Fujimura Y., Eguchi T., Yoshida N., et al. IL-18 induces apoptosis of adherent bone marrow cells in TNF-alpha mediated osteoclast formation in synergy with IL-12. Immunol Lett 2006, 107:22-31.
22. Dunn G.P., Koebel C.M., Schreiber R.D. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006, 6:836-848.
23. Billiau A., Heremans H., Vermeire K., Matthys P. Immunomodulatory Properties of Interferon-gamma: an update. Ann N Y Acad Sci 1998, 856:22-32.
24. Takayanagi H., Ogasawara K., Hida S. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000, 408:600-605.
25. Vermeire K., Heremans H., Vandeputte M., Huang S., Billiau A., Matthys P. Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J Immunol 1997, 158:5507-5513.
26. Gao Y., Grassi F., Ryan M., Terauchi M., Page K., Yang X., et al. IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest 2007, 117:122-132.
27. Masuyama R., Vriens J., Voets T., Karashima Y., Owsianik G., Vennekens R., et al. TRPV4-madiated calcium influx regulates terminal differentiation of osteoclasts. Cell Metab 2008, 8:257-265.
28. Nagafuji K., Shibuya T., Harada M., Mizuno S., Takenaka K., Miyamoto T., et al. Functional expression of Fas antigen (CD95) on hematopoietic progenitor cells. Blood 1995, 86:883-889.
29. Krum S.A., Miranda-Carboni G.A., Hauschka P.V., Carroll J.S., Lane T.F., Freedman L.P., et al. Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J 2008, 27:535-545.
30. Yoshimatsu M., Kitaura H., Fujimura Y., Eguchi T., Kohara H., Morita Y., et al. IL-12 inhibits TNF-alpha induced osteoclastogenesis via a T cell-independent mechanism in vivo. Bone 2009, 45:1010-1016.
31. Mavropoulos A., Sully G., Cope A.P., Clark A.R. Stabilization of IFN-gamma mRNA by MAPK p38 in IL-12- and IL-18-stimulated human NK cells. Blood 2005, 105:282-288.
32. Nakahira M., Ahn H.J., Park W.R., Gao P., Tomura M., Park C.S., et al. Synergy of IL-12 and IL-18 for IFN-gamma gene expression: IL-12-induced STAT4 contributes to IFN-gamma promoter activation by up-regulating the binding activity of IL-18-induced activator protein 1. J Immunol 2002, 168:1146-1153.
33. Morinobu A., Gadina M., Strober W., Visconti R., Fornace A., Montagna C., et al. STAT4 serine phosphorylation is critical for IL-12-induced IFN-gamma production but not for cell proliferation. Proc Natl Acad Sci USA 2002, 99:12281-12286.
34. Xu G., Zhang Y., Zhang L., Ren G., Shi Y. Bone marrow stromal cells induce apoptosis of lymphoma cells in the presence of IFNgamma and TNF by producing nitric oxide. Biochem Biophys Res Commun 2008, 375:666-670.
35. Sato K., Satoh T., Shizume K., Yamakawa Y., Ono Y., Demura H., et al. Prolonged decrease of serum calcium concentration by murine gamma-interferon in hypercalcemic, human tumor (EC-GI)-bearing nude mice. Cancer Res 1992, 52:444-449.
36. Tohkin M., Kakudo S., Kasai H., Arita H. Comparative study of inhibitory effects by murine interferon gamma and a new bisphosphonate (alendronate) in hypercalcemic, nude mice bearing human tumor (LJC-1-JCK). Cancer Immunol Immunother 1994, 39:155-160.
37. Rodriguiz R.M., Key L.L., Ries W.L. Combination macrophage-colony stimulating factor and interferon-gamma administration ameliorates the osteopetrotic condition in microphthalmic (mi/mi) mice. Pediatr Res 1993, 33:384-389.
38. Madyastha P.R., Yang S., Ries W.L., Key L.L. IFN-gamma enhances osteoclast generation in cultures of peripheral blood from osteopetrotic patients and normalizes superoxide production. J Interferon Cytokine Res 2000, 20:645-652.
39. Mann G.N., Jacobs T.W., Buchinsky F.J., Armstrong E.C., Li M., Ke H.Z., et al. Interferon-gamma causes loss of bone volume in vivo and fails to ameliorate cyclosporin A-induced osteopenia. Endocrinology 1994, 135:1077-1083.
40. Goodman G., Dissanayake I., Gorodetsky E., Zhou H., Ma Y., Jee W., et al. Interferon-alpha, unlike interferon-gamma, does not cause bone loss in the rat. Bone 1999, 25:459-463.
41. Kotake S., Nanke Y., Mogi M., Kawamoto M., Furuya T., Yago T., et al. IFN-gamma-producing human T cells directly induce osteoclastogenesis from human monocytes via the expression of RANKL. Eur J Immunol 2005, 35:3353-3363.